Västra Hamnen Corporate Finance
Capital Markets Transactions and M&As
Recent research
aXichem: Setback contrasted with success
During December 2023, aXichem received a message from EFSA regarding the application for approval for aXiphen within Europe, which was assessed as "inconclusive". This notification means that the company must provide EFSA with additional data, a process that the company has initiated. The use of aXiphen as a raw material in zootechnical feed additives was approved in Brazil only a few days later.
Movinn: Focus on existing markets
Movinn’s fourth quarter of 2023 concluded a turbulent year. After impressive growth in 2022, the focus for last year was on portfolio optimisation. Due to various external and internal factors, the company was not able to execute its strategic plan. Looking towards 2024, the strategy remains similar to 2023, with a focus on existing markets, portfolio optimisation and fewer added units.
Xintela: Awaiting results in trials and discussions
During Q4 2023, Xintela's project progressed according to plan. To meet the short-term capital requirement, the company raised a loan of SEK 16.5 million from Flerie Invest, Xintela's main owner.
Serstech: Breaking even into 2024
Serstech has had a strong start to the year with significant deals during the first month of 2024 already making this the second-best year of the company’s history in terms of total order value.
Market Focus
Market focus is our service for stock analysis of small and medium-sized listed companies. The service contributes to increased turnover in the share by increasing investors' awareness of the company and attention to current events. All our analyses are listed below.
Market Focus
Register for Market Focus updates
About us
We help our customers grow
Västra Hamnen Corporate Finance is an independent securities company that provides advice in connection with corporate transactions.